News

Posted on: May 6, 2020

The emerging and evolving coronavirus disease 2019 (COVID-19) pandemic has created a global public health emergency1. There is an urgent need to understand the underlying determinants of the outcome of COVID-19 and how this translates to individuals who are treated with immunomodulating medications. This information will be vital for informing assessments of risk of COVID-19 […]

» More Details
Posted on: March 27, 2020

Dear IEC Friends, In this difficult and uncertain time, IEC would like to provide guidance on the use of systemic treatments for atopic dermatitis (AD; commonly called eczema) in the context of the COVID-19 pandemic, based on currently available pandemic and pharmacologic information. Individuals with AD using immunosuppressive medications should be advised by their physician […]

» More Details
Posted on: September 20, 2019

Webcasts of IEC symposia on “New Topical Developments and Preventive Mechanisms” and “Atopic Dermatitis Comorbidities” now available on-demand.

» More Details
Posted on: May 31, 2018

The International Eczema Council is providing two new educational modules for atopic dermatitis (AD) clinical investigators.

» More Details